The purpose of this study is to assess the safety and efficacy of bimatoprost in patients with glaucoma or ocular...
Date First Received: March 7, 2006
Last Updated: September 25, 2007
Verified by: Allergan, August 2007
Clinical Trial Phase: Phase 2/Phase 3 | Start Date:
Overall Status: Completed
Estimated Enrollment: 550
Brief Summary
Condition Keyword(s):
Intervention(s):
The purpose of this study is to assess the safety and efficacy of bimatoprost in patients with glaucoma or ocular hypertension
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Intervention(s) in this Clinical Trial
- Drug: bimatoprost
Outcome Measures for this Clinical Trial
Primary Measures
- Lowering intraocular pressure (IOP)
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- Clinical diagnosis of glaucoma or ocular hypertension in both eyes
- Patient requires IOP-lowering drug in both eyes
Exclusion Criteria:
- Uncontrolled medical conditions
- Ocular seasonal allergies within the past 2 years
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: N/A
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Sponsor Information
Lead Sponsor: Allergan
Additional Information
Information obtained from ClinicalTrials.gov on August 20, 2008
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00300443
Study ID Number: 192024-031
ClinicalTrials.gov Identifier: NCT00300443
Health Authority: United States: Food and Drug Administration
Clinical Trials Authorship and Review
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
